"Practical Applications of Mitochondria Research in Sports and Enhanced Performance" is an upcoming conference taking place June 11, 2021 (5 pm - 7.45 pm, BST) where professionals from Aging Analytics Agency and invited guest speakers will share insights, findings and personal experiences about the Role of Mitochondria Research in Sports Medicine, Enhanced Performance and Practical Human Longevity.
5:00 - 5:10: Kate Batz (Managing Partner, Longevity.Capital), Franco Cortese (Director, Aging Analytics Agency)
5:10 - 5:30: Dmitry Kaminskiy (General Partner, Deep Knowledge Group)The Inevitable Convergence Between Practical Longevity and Performance Enhancement
5:30 - 5:50: Dr. Arkadi Prokopov
Scientific and Technical Results of MitoPro Method for Performance Enhancement in Elite Athletes
5:50 - 6:05: Dr. Michael Zemel (Chief Scientific Officer, NuSirt BioPharma)
6:05 - 6:20: Dr. James Carroll (Chief Executive Officer, Thor)
6:20 - 6:35: Dr. Thomas Seoh (Chief Executive Officer, Kinexum)
6:35 - 6:50: David Brown, Ph.D., Senior Director, Scientific and Technical Innovation at Stealth BioTherapeutics
6:50 - 6:55: Kate Batz (Managing Partner, Longevity.Capital), Franco Cortese (Director, Aging Analytics Agency)
Introduction to Panel Discussion
6:55 - 7:35: Panel Discussion
7:35 - 7:45: Kate Batz (Managing Partner, Longevity.Capital), Franco Cortese (Director, Aging Analytics Agency)
Dr. Thomas Seoh
Chief Executive Officer at Kinexum
Thomas Seoh is an entrepreneur/executive who has held senior leadership positions in public and private, pharmaceutical, biotech and medical device companies for over 25 years. After practicing corporate law in New York and London and serving as General Counsel for several companies, including Viratek in Costa Mesa, which developed the antiviral, VIRAZOLE®, and engaged in antisense oligonucleotide research, he joined Guilford Pharmaceuticals in Baltimore, which commercialized GLIADEL® wafer for glioblastoma multiforme and developed the propofol pro-drug LUSEDRA® and small molecules for Parkinson’s disease. Thomas began as Guilford's VP, General Counsel and Secretary, and later served as SVP Corporate and Commercial Development. Thomas holds an AB in Philosophy and History and a JD from Harvard University.
Dr. Michael B. Zemel
Ph.D., Chief Scientific Officer at NuSirt BioPharma
Michael B. Zemel is a Chief Scientific Officer of NuSirt and a CSO of Kinexum.He founded NuSirt Sciences following a 30+ year academic career with the intent of translating molecular and cellular studies of energy sensing and metabolism into concrete solutions for diseases of over-nutrition and aging.
He has lead both the discovery and translational programs for NuSirt, resulting in significant intellectual property development; these efforts have led to 25 US patents (with corresponding international patents) granted since 2012, most of which have been successfully translated into clinical assets in obesity, NASH and diabetes.
Dr. James Carroll
Chief Executive Officer at Thor
James Carroll is an internationally recognized authority on Photobiomodulation (PBM) / Low Level Laser Therapy (LLLT) who collaborates with many universities and research centers on PBM, including Harvard Medical School and School of Public Health, MIT, Massachusetts General Hospital, and Leiden University Medical Centre (in Amsterdam). James is one of the most recognized authorities in the world on PBM’s low level light therapies mechanisms of action, dose, dose rate effects and the measurement and reporting of parameters.
He is the Biomedical Optics Society Conference Chairman and founded THOR Photomedicine Ltd.in June of 1998 and has been the Chief Executive Officer since its inception.
Ph.D., Senior Director, Scientific and Technical Innovation at Stealth
A scientist, communicator, and innovator specializing in rare diseases. An expert in metabolism, notably inherited and acquired mitochondrial diseases.
Technical expertise spans basic science through transnational clinical endpoints, and is used to advance discovery pipelines, educate others, and track emerging technologies. Established author of scientific manuscripts, regulatory documents, medical affairs training modules, and corporate presentations. Fascinated by innovative mitochondrial medicines and relentless in pursuit of novel rare disease therapies.
Dr. Arkadi Prokopov
Expert Longevity Practitioner
Dr. Arkadi Prokopov is biogerontologist, mitochondrial researcher and physician for integrative medicine with three decades of experience in normobaric intermittent hypoxic training/therapy.
General Partner at Deep Knowledge Group
Dmitry Kaminskiy is an innovative entrepreneur and investor active in the fields of Longevity, Precision Medicine, and Artificial Intelligence. He is co-founder and managing partner at Deep Knowledge Ventures, a leading investment fund focused on DeepTech, renowned for its use of sophisticated analytical systems for investment target identification and due-diligence.
He is a frequent speaker on AI and Longevity, including events organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, Financial Times “Global Pharmaceutical and Biotechnology Conference”, the "Precision Medicine World Conference" in Silicon Valley as well as others at Oxford and Cambridge Universities.